Market Overview

Regeneron Pharmaceuticals Spokesperson Declines Comment on Earlier Takeover Chatter

Share:
Related REGN
Regeneron Bounces Higher Off Support
Biotech Bubble Valuations From Sam Islay
Will Eylea Sales Drive Regeneron (REGN) Q1 Earnings? - Analyst Blog (Zacks)
Related SNY
Genzyme Initiates Phase 2a Clinical Trial to Evaluate Oral Therapy for Fabry Disease
CVS Says New Cholesterol Drug Types Could Be Costly
Tracking Ken Fisher's Fisher Asset Management Portfolio - Q1 2015 Update (Seeking Alpha)

Regeneron (NASDAQ: REGN) spokesperson Peter Dworkin, while declining comment on earlier takeover chatter involving Sanofi (NYSE: SNY), did say that the two companies have a solid working relationship and have stated it would be advantageous to keep the relationship going as it is now, as separate companies.

Sanofi is Regeneron's largest shareholder currently. There is a standstill agreement in place preventing Sanofi from acquiring more than 30% of Regeneron's shares.

Regeneron shares spiked to a high of $145.81 on Thursday.

Posted-In: News Rumors M&A Movers

 

Related Articles (REGN + SNY)

Around the Web, We're Loving...

Get Benzinga's Newsletters